More molecular glue: Plexium pens AbbVie pact months after Amgen deal
A few months after its deal with Amgen, San Diego-based biotech Plexium has inked a deal with another Big Pharma – this time, it’s AbbVie.
While Amgen’s deal focused on the cancer space, AbbVie hopes to use Plexium’s “agnostic” targeted protein degradation (TPD) platform to screen for new therapies for neurological diseases, Plexium announced today.
The deal includes $35 million upfront and $530 million in downstream milestones, along with future royalties for each of the five unspecified targets that Plexium will be screening for new therapies, Plexium CEO Percival Barretto-Ko told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.